BackgroundPulmonary abnormalities are often present in patients infected with the human immunodeficiency virus (HIV). ObjectivesThe aim of the study was to determine the prevalence and characteristics of, and risk factors for, pulmonary abnormalities in HIV-positive patients. MethodsA total of 275 HIV-positive patients [mean (± standard deviation) age 48.5 ± 6.6 years] were included in the study, of whom 95.6% had been receiving highly active antiretroviral therapy (HAART) for a mean (± standard deviation) duration of 11.9 ± 5.4 years. The median (interquartile range) CD4 lymphocyte count was 541 (392-813) cells/μL, and 92% of the patients had an undetectable viral load. We determined: (1) spirometry, static lung volumes, lung diffusing capacity, pulmonary gas exchange and exercise tolerance, and (2) the amount of emphysema via a computed tomography (CT) scan. ResultsChronic cough and expectoration (47%) and breathlessness during exercise (33.9%) were commonly reported. Airflow limitation (AL) was present in 17.2%, low pulmonary diffusing capacity in 52.2% and emphysema in 10.5−37.7% of patients, depending on the method used for quantification. Most of these abnormalities had not been diagnosed or treated previously. Smoking exposure and previous tuberculosis were the main risk factors for AL, whereas smoking exposure and several variables related to HIV infection appeared to contribute to the risk of emphysema and low diffusing capacity. ConclusionsDespite HAART, pulmonary structural and functional abnormalities are frequent in HIV-positive patients. They are probably attributable to both environmental (smoking and tuberculosis) and HIV-related factors. Most of these abnormalities remain unnoticed and untreated. Given the relatively young age of these patients, these results anticipate a significant health problem in the next few years as, thanks to the efficacy of HAART, patients survive longer and experience the effects of aging.Keywords: airflow limitation, chronic obstructive pulmonary disease, emphysema, HIV, tuberculosis, smoking IntroductionAIDS remains a challenge for health care systems around the world as a consequence of its health and also its social impact [1,2]. During the early years of the pandemic, Pneumocystis jirovecii (formerly Pneumocystis carinii) pneumonia, tuberculosis, bacterial pneumonia and Kaposi's sarcoma were the major causes of morbidity and mortality [3]. The introduction of highly active antiretroviral therapy (HAART) considerably improved the prognosis and quality of life of HIV-infected patients [4,5]. Previous studies have identified a high prevalence of airflow limitation (AL) and pulmonary emphysema in patients infected with HIV [6][7][8][9][10][11][12][13][14][15]. Yet, lung function assessment has not been included in large multicentre studies aimed at characterizing events not directly related to HIV infection in these patients [16,17]. Lung function testing is also not normally considered part of the routine clinical assessment of these patients, despite the availabili...

No abstract

Antiretroviral therapy and PPV have a significant, independent protective effect against pneumococcal disease, regardless of CD4 lymphocyte count; thus, all patients with HIV infection should be vaccinated with PPV to prevent pneumococcal disease.

This is an open access article under the terms of the Creat ive Commo ns Attri bution-NonCo mmercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.